Die #1 Medizintourismusplattform seit 2014

Beste Medulloblastom Onkologen - TOP-85 Ärzte

author
Der Inhalt entspricht den Redaktionsrichtlinien von Bookimed und wurde auf Qualität geprüft
Fahad Mawlood - Allgemeinarzt. Gewinner von 4 wissenschaftlichen Preisen. Er diente in Westasien. Ehemaliger Teamleiter eines medizinischen Teams zur Betreuung arabischsprachiger Patienten. Jetzt Fahad ist verantwortlich für die Datenverarbeitung und die Genauigkeit der medizinischen Inhalte.
image
Dror Levin
Pädiatrischer Hämatologe/-in
39 Jahre der Erfahrung
4.4
138 Rezensionen
Israel, Tel Aviv
Sourasky Medical Center

Dror Levin

Pädiatrischer Hämatologe/-in
39 Jahre der Erfahrung

Dr. Dror Levin ist leitender Kinderarzt und Direktor der Behandlungsabteilungen für Blutkrankheiten und Knochenkrebs (Sarkom) im Kinderkrankenhaus „Dana“ bzw. im medizinischen Zentrum „Sourasky“. Er ist Facharzt für Kindermedizin, Hämatologie und Onkologie und hat zusätzliche Auslandserfahrung am Orthopädischen Institut Rizzoli in Italien.

Mehr lesen
image
Shlomi Constantini
Neurochirurg/-in
40 Jahre der Erfahrung
4.4
138 Rezensionen
Israel, Tel Aviv
Sourasky Medical Center

Shlomi Constantini

Neurochirurg/-in
40 Jahre der Erfahrung

Akkredititationen:

Congress of Neurological Surgeons
American Association of Neurological Surgeons
European Society of Pediatric Neurosurgery
International Federation of Neuroendoscopy

Professor Shlomi Constantini ist eine hochqualifizierte Neurochirurgin in Israel mit Fachkenntnissen in allgemeiner und pädiatrischer Neurochirurgie, mikrochirurgischen Operationen, rekonstruktiven Eingriffen und Behandlungen von Hirn- und Wirbelsäulentumoren. Er hat mehrere Auszeichnungen erhalten und ist Mitglied mehrerer Berufsverbände.

Mehr lesen
image
Deniz Konya
Neurochirurg/-in
74 Jahre der Erfahrung
4.2
22 Rezensionen
Türkei, Istanbul
Medical Park Göztepe Hospital Complex

Deniz Konya

Neurochirurg/-in
74 Jahre der Erfahrung

Spinaler Neurochirurg

Mehr lesen
image
Sener Cihan
Klinischer Onkologe/-in
31 Jahre der Erfahrung
5.0
1 Rezensionen
Türkei, Istanbul
Istinye University Medical Park Gaziosmanpasa Hospital

Sener Cihan

Klinischer Onkologe/-in
31 Jahre der Erfahrung

AREAS OF INTEREST

  • Breast cancer
  • Colon cancer
  • Lung cancer
  • Malignant melanoma
  • Urogenital cancers
  • Gynecological cancers
  • Digestive system cancers

 

Education and Specialization

  • 1987-1993 BSc Faculty of Medicine, Uludağ University Faculty of Medicine
  • 1994-1999 BSc Internal Medicine Ondokuz Mayıs University Faculty of Medicine
  • 2008-2011 PhD Medical Oncology Ankara Numune Training and Research Hospital
  • 2016 Assoc. Prof. / Prof. Dr. Medical Oncology Okmeydanı Training and Research Hospital

 

Experience

  • 1993-1994 General Practitioner Senirkent State Hospital Senirkent, Isparta
  • 1994-1999 Research Position Ondokuz Mayıs University Faculty of Medicine Internal Medicine Department, Samsun
  • 2000-2006 Specialist Doctor Diyarbakır SSK Hospital, Diyarbakır
  • 2006-2008 Specialist Doctor Diyarbakır State Hospital, Diyarbakır
  • 2008-2011 Dr. Minor Assistant Ankara Numune Training and Research Hospital
  • 2011-2013 Specialist Doctor Diyarbakır Training and Research Hospital, Medical Oncology
  • 2013- 2016 Specialist Doctor Okmeydanı Training and Research Hospital, Medical Oncology Clinic
  • 2016 Education Manager Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Assoc. Prof.

 

Professional Memberships

Turkish Society of Medical Oncology

 

Education and Training:

  • Medical Degree: Graduated from Uludağ University Faculty of Medicine in 1993.
  • Specialization in Internal Medicine: Completed at Ondokuz Mayıs University Faculty of Medicine in 1999.
  • Medical Oncology Fellowship: Completed at Ankara Numune Research and Training Hospital in 2011.
  •  
  • Professional Experience:
  • Isparta Senirkent State Hospital: Completed his mandatory service as an Internal Medicine Specialist and Hemodialysis Responsible Physician (1993-1994).
  • Prof. Dr. Gazi Yaşargil Training and Research Hospital: Served as a Medical Oncologist (2011-2013).
  • Okmeydanı Research and Training Hospital: Achieved the title of Associate Professor and later full Professor, significantly contributing to medical oncology (2013-2016).
  • Current Position: Professor of Medical Oncology at İstinye University Hospital Medical Park Gaziosmanpaşa, Istanbul, where he continues to provide top-tier oncology care and mentorship.

 

Areas of Expertise:

  • Cancer Treatment: Specializes in the treatment of various cancers, including breast, colon, lung, malignant melanoma, urogenital, gynecological, and gastrointestinal cancers.
  • Advanced Therapies: Proficient in administering chemotherapy, immunotherapy, and other cutting-edge treatments for cancer patients.
  • Research and Education: Actively involved in cancer research and dedicated to educating the next generation of oncologists, continuously enhancing the field through both clinical practice and academic contributions.

 

  • Extensive Experience:
  •  
  • With over 24 years of medical practice, Prof. Dr. Cihan is a highly respected figure in oncology, known for his comprehensive approach to cancer treatment.
  • International Recognition: Participates in numerous international seminars and congresses, keeping abreast of the latest advancements in oncology.
  • Patient-Centric Care: Renowned for his compassionate and personalized approach to patient care, ensuring tailored treatment plans that address the unique needs of each patient.
  • Multidisciplinary Collaboration: Works with a multidisciplinary team of experts at Medical Park, providing holistic and coordinated care to achieve the best possible outcomes for patients.

 

 

Achievements and Awards:

  • Academic Contributions: Has contributed significantly to oncology literature and research, with numerous publications in reputable medical journals.
  • Leadership in Oncology: Recognized for his leadership in oncology, both in clinical settings and academic institutions, influencing cancer treatment practices and policies.
Mehr lesen
image
Inta Jaunalksne
Klinischer Onkologe/-in
47 Jahre der Erfahrung
Lettland, Jurmala
Pallas Clinic

Inta Jaunalksne

Klinischer Onkologe/-in
47 Jahre der Erfahrung
Dr. Inta Jaunalksne ist Immunologin mit mehr als 30 Jahren Erfahrung und spezialisiert auf Virotherapie. Er ist Absolvent des Riga Medical Institute, absolvierte ein Praktikum in Innerer Medizin und ist Leiter des Clinical Immunology Center am Pauls Stradins Clinical University Hospital.Mehr lesen
image
Osman Kostek
Klinischer Onkologe/-in
20 Jahre der Erfahrung
5.0
1 Rezensionen
Türkei, Istanbul
Medipol Acibadem Bezirkskrankenhaus

Osman Kostek

Klinischer Onkologe/-in
20 Jahre der Erfahrung

Education

  • (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
  • (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

Career

  • (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
  • (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
  • (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
  • (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye
Mehr lesen
image
Edmundo Pichardo
Schönheitschirurg/-in
37 Jahre der Erfahrung
Mexiko, Mexiko-Stadt
Klinik von DR. IRERI ASTEINZA

Edmundo Pichardo

Schönheitschirurg/-in
37 Jahre der Erfahrung
Bauchdeckenstraffung
Bauchdeckenstraffung
Bauchdeckenstraffung
image
Hamza Ugur Bozbey
Klinischer Onkologe/-in
10 Jahre der Erfahrung

Hamza Ugur Bozbey

Klinischer Onkologe/-in
10 Jahre der Erfahrung
Türkei, Istanbul
Uniqacare Clinic
image
Muhammed Gomec
Dickdarmchirurg/-in
15 Jahre der Erfahrung
5.0
1 Rezensionen

Muhammed Gomec

Dickdarmchirurg/-in
15 Jahre der Erfahrung
Türkei, Sivas
Medicana Sivas Hospital
image
Oscar Arrieta
Klinischer Onkologe/-in
31 Jahre der Erfahrung

Oscar Arrieta

Klinischer Onkologe/-in
31 Jahre der Erfahrung
Mexiko, Mexiko-Stadt
Klinik von DR. IRERI ASTEINZA
image
Alandag Celal
Klinischer Onkologe/-in
15 Jahre der Erfahrung
5.0
1 Rezensionen

Alandag Celal

Klinischer Onkologe/-in
15 Jahre der Erfahrung
Türkei, Sivas
Medicana Sivas Hospital
image
Nail Paksoy
Onkologe/Mammologe/-in
13 Jahre der Erfahrung
5.0
2 Rezensionen
Türkei, Istanbul
Medipol Bahçelievler Hospital

Nail Paksoy

Onkologe/Mammologe/-in
13 Jahre der Erfahrung

Akkredititationen:

ESMO Board Certification in Medical Oncology


PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

 

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

 

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

  • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
  • Role: Subinvestigator

2. PFİZER

  • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
  • Role: Subinvestigator

3. RECITE - AMGEN

  • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
  • Role: Subinvestigator

4. NAVIGATE - BAYER

  • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
  • Role: Subinvestigator

5. RUBY - Tesaro (PRA)

  • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
  • Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

  • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
  • Role: Subinvestigator

7. ASTRA ZENECA

  • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
  • Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

  • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
  • Role: Subinvestigator
  •  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
  • Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
  • Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

  • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
  • Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

  • Authors: Paksoy, Nail, et al.
  • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

  • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
  • Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

  • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
  • Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

  • Authors: HAS SIMSEK, Duygu, et al.
  • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

  • Authors: FERHATOGLU, Ferhat, et al.
  • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

  • Authors: GÜRBÜZ, Mustafa, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

  • Authors: AY, Seval, et al.
  • Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

  • Authors: CIL, Ibrahim, et al.
  • Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

  • Authors: HIZAL, Mutlu, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
  • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
  • Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

  • Authors: DEMIR, Semra, et al.
  • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

  • Authors: ÖZDEMIR, Seçil Kepil, et al.
  • Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

  • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
  • Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

  • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
  • Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
  • Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
  • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

  • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
  • Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

  • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
  • Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

  • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
  • Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

  • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
  • Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

  • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
  • Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

 

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

  • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

  • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

  • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

  • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

  • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

  • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

  • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

  • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

 

 

Mehr lesen
5.0
2 Rezensionen
Arztbesuch preis auf anfrage
Strahlentherapie bei Darmkrebs $4000 - $6000
Kraniotomie $10000 - $15000
Weitere Behandlungen
image
Seyda Gunduz
Klinischer Onkologe/-in
14 Jahre der Erfahrung
4.3
16 Rezensionen

Seyda Gunduz

Klinischer Onkologe/-in
14 Jahre der Erfahrung
Türkei, Istanbul
Istinye Universität Liv Krankenhaus Bahcesehir
image
Jorge Diamantopoulos
4.6
16 Rezensionen
Spanien, Madrid
HM Hospitales
  • Spezialisiert auf die Behandlung von Medulloblastomen mit Operation, Chemotherapie und Bestrahlung.
  • Die internationale Praxis in den USA, Großbritannien und Spanien erweitert seine Expertise.
  • Anerkannt für fortschrittliche neurochirurgische Methoden, die auf das Medulloblastom zugeschnitten sind.
  • Fachärztin für Neurochirurgie mit Schwerpunkt auf Hirntumoren bei Kindern.
  • Mitglied angesehener neurochirurgischer Gesellschaften, der zur onkologischen Forschung beiträgt.
  • Bietet Online-Konsultationen für Patienten mit Medulloblastom weltweit an.
  • Fließende Englisch- und Spanischkenntnisse sorgen für eine klare Kommunikation mit den Patienten.
Mehr lesen
image
Gerd Manthei
4.2
15 Rezensionen
Deutschland, Hamburg
Asklepios St. Georg Hospital

Neurochirurg

Mehr lesen
image
Jacob Zauberman
5.0
2 Rezensionen
Israel, Ramat Gan
Sheba Medical Center

Akkredititationen:

American Association for the Surgery of Trauma

Dr. Jacob Zauberman ist ein sehr erfahrener Neurochirurg, der sich auf Hirntumore, Epilepsie, endoskopische Operationen und die Behandlung von Hydrozephalus spezialisiert hat. Er absolvierte die Medizinische Fakultät des Technion in Israel und studierte an der BYU und am Seattle Children's Hospital in den USA. Er ist Mitglied der Israeli Association of Neurosurgeons, der American Neurosurgical Association und der American Association for the Surgery of Trauma.

Mehr lesen
image
Sergei Postovskiy
5.0
1 Rezensionen
Israel, Haifa
Rambam Medical Center

Stellvertretender Leiter. der Abteilung für Pädiatrische Hämatologie

Mehr lesen
image
Do Hyun Nam
Pädiatrischer Neurochirurg/-in
4.5
22 Rezensionen
Republik Korea, Seoul
Samsung Medical Center

Do Hyun Nam

Pädiatrischer Neurochirurg/-in
Dr. Do Hyun Nam ist ein führender Neurochirurg für Kinder und Erwachsene in Südkorea, spezialisiert auf endoskopische Operationen, Entfernung von Hirntumoren und Radiochirurgie für gutartige und bösartige Tumore.Mehr lesen
image
Sebastian Keil
Strahlenonkologe/-in
20 Jahre der Erfahrung
4.6
56 Rezensionen
Deutschland, Solingen
Krankenhaus Solingen (Medical Center in Solingen)

Sebastian Keil

Strahlenonkologe/-in
20 Jahre der Erfahrung

Radiologe. Hören Sie vom Institut für Diagnostische und Interventionelle Radiologie

Mehr lesen
image
Kadir Şenses
Strahlenonkologe/-in
36 Jahre der Erfahrung
3.5
3 Rezensionen
Türkei, Istanbul
Istanbul Oncology Hospital

Kadir Şenses

Strahlenonkologe/-in
36 Jahre der Erfahrung
Dr. A. Kadir Senses ist ein Spezialist für Radioonkologie, der seine medizinische Ausbildung an der Medizinischen Fakultät der Karadeniz-Universität und seine Facharztausbildung an der Medizinischen Fakultät der Cerrahpaşa-Universität Istanbul, Abteilung für Radioonkologie, abgeschlossen hat. Er hat in verschiedenen onkologischen Zentren gearbeitet und ist seit 2008 Spezialist für Radioonkologie am Maltepe-Istanbul Oncology Hospital.Mehr lesen